Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up. (BERVOLT study: Bevacizumab for RVO long-term follow-up)

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 254, Issue 5, 2016, Pages 835-844

  Kornhauser, Tom ^a   Schwartz, Roy ^b   Goldstein, Michaella ^b   Neudorfer, Meira ^b   Loewenstein, Anat ^b   Barak, Adiel ^b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Bevacizumab; BRVO; CME; CRVO; Injections; RVO

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CATARACT; CENTRAL MACULAR THICKNESS; CENTRAL RETINA VEIN OCCLUSION; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; EYE INFLAMMATION; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; LENS DISEASE; MACULAR EDEMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA TEAR; RETROSPECTIVE STUDY; VISUAL ACUITY; VITREOUS HEMORRHAGE; ANTAGONISTS AND INHIBITORS; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINAL VEIN OCCLUSION; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84939222229     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-015-3130-z     Document Type: Article

References (20)

1. Cugati S, Wang JJ, Rochtchina E, Mitchell P (2006) Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol 124:726–732. doi:10.1001/archopht.124.5.726
2. The Royal College of Ophthalmologists, Interim Guidelines for Management of Retinal Vein Occlusion, December 2010. https://www.rcophth.ac.uk/wp-content/uploads/2014/12/2010-SCI-095-RVO-Interim-Guidelines-Dec-2010-FINAL.pdf. Accessed 6 May 2015
3. Lucentis 10 mg/ml solution for injection - Summary of Product Characteristics (SPC) - (eMC). https://www.medicines.org.uk/emc/medicine/19409. Accessed 6 May 2015
4. Eylea 40mg/ml solution for injection in a vial - Summary of Product Characteristics (SPC) - (eMC). https://www.medicines.org.uk/emc/medicine/27224. Accessed 6 May 2015
5. Campochiaro PA, Heier JS, Feiner L et al (2010) Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion. Six-Month Primary End Point Results of a Phase III Study. Ophthalmology 117:1102–1112.e1. doi:10.1016/j.ophtha.2010.02.021
6. Brown DM, Campochiaro PA, Singh RP et al (2010) Ranibizumab for Macular Edema following Central Retinal Vein Occlusion. Six-Month Primary End Point Results of a Phase III Study. Ophthalmology. doi:10.1016/j.ophtha.2010.02.022
7. Heier JS, Campochiaro PA, Yau L et al (2012) Ranibizumab for macular edema due to retinal vein occlusions: Long-term follow-up in the HORIZON trial. Ophthalmology 119:802–809. doi:10.1016/j.ophtha.2011.12.005
8. Rosenfeld PJ, Fung AE, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36:336–339
9. PAT survey highlights shifting trends in practice preferences | OSN Retina. http://www.healio.com/ophthalmology/retina-vitreous/news/print/osn-retina/%7B857f9212-d7f4-4cff-b9f3-6d0f85748c8a%7D/pat-survey-highlights-shifting-trends-in-practice-preferences. Accessed 6 May 2015
10. Epstein DL, Algvere PV, Von Wendt G et al (2012) Benefit from bevacizumab for macular edema in central retinal vein occlusion: Twelve-month results of a prospective, randomized study. Ophthalmology 119:2587–2591. doi:10.1016/j.ophtha.2012.06.037
11. Prager F, Michels S, Kriechbaum K et al (2009) Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol. doi:10.1136/bjo.2008.141085
12. Zhang H, Liu Z-L, Sun P, Gu F (2011) Intravitreal bevacizumab for treatment of macular edema secondary to central retinal vein occlusion: eighteen-month results of a prospective trial. J Ocul Pharmacol Ther 27:615–621. doi:10.1089/jop.2011.0050
13. Braithwaite T, Nanji AA, Greenberg PB (2010) Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst Rev CD007325. doi:10.1002/14651858.CD007325.pub2
14. Pielen A, Feltgen N, Isserstedt C et al (2013) Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review. PLoS One 8:e78538. doi:10.1371/journal.pone.0078538
15. Brown DM, Wykoff CC, Wong TP, et al. (9000) Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: The Rubeosis Anti-VEGF (RAVE) Trial. Retina. doi:10.1097/IAE.0000000000000191
16. Campochiaro PA, Brown DM, Awh CC et al (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: Twelve-month outcomes of a phase III study. Ophthalmology 118:2041–2049. doi:10.1016/j.ophtha.2011.02.038
17. Brown DM, Campochiaro PA, Bhisitkul RB et al (2011) Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 118:1594–1602. doi:10.1016/j.ophtha.2011.02.022
18. Central T, Occlusion V, Group S, Library PM (1997) Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. Arch Ophthalmol 115:486–91
19. Hayreh SS (2014) Ocular vascular occlusive disorders: Natural history of visual outcome. Prog Retin Eye Res 41C:1–25. doi:10.1016/j.preteyeres.2014.04.001
20. Hayreh SS, Rojas P, Podhajsky P et al (1983) Ocular neovascularization with retinal vascular occlusion-III. Incidence of ocular neovascularization with retinal vein occlusion. Ophthalmology 90:488–506